AstraZeneca: Daiichi and AstraZeneca's Enhertu gains EC approval for breast cancers
The EC has approved Daiichi Sankyo and AstraZeneca's Enhertu for use as a single agent to treat adults with certain breast cancers.
Read full article »
CEO
Pascal Soriot
AstraZeneca is an England-based biopharmaceutical company that researches and develops prescription medicines for the treatment of cancer and renal diseases.
Read more